Y.D. More Investments Ltd Has $132,000 Position in Eli Lilly and Company (NYSE:LLY)

Y.D. More Investments Ltd boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 25.7% in the fourth quarter, Holdings Channel.com reports. The fund owned 171 shares of the company’s stock after buying an additional 35 shares during the quarter. Y.D. More Investments Ltd’s holdings in Eli Lilly and Company were worth $132,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in LLY. Weaver Capital Management LLC boosted its position in shares of Eli Lilly and Company by 32.9% in the 4th quarter. Weaver Capital Management LLC now owns 2,342 shares of the company’s stock worth $1,808,000 after purchasing an additional 580 shares during the last quarter. Hager Investment Management Services LLC acquired a new position in Eli Lilly and Company in the fourth quarter valued at about $4,486,000. Stratos Investment Management LLC boosted its holdings in Eli Lilly and Company by 1.5% during the fourth quarter. Stratos Investment Management LLC now owns 7,014 shares of the company’s stock worth $5,415,000 after buying an additional 104 shares during the last quarter. Guidance Capital Inc. acquired a new position in shares of Eli Lilly and Company during the 4th quarter worth about $933,000. Finally, Cassia Capital Partners LLC increased its stake in shares of Eli Lilly and Company by 32.4% in the 4th quarter. Cassia Capital Partners LLC now owns 1,343 shares of the company’s stock valued at $1,037,000 after acquiring an additional 329 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

LLY has been the topic of several recent analyst reports. Truist Financial boosted their price objective on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a report on Monday. Bank of America reissued a “buy” rating and issued a $997.00 price target on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Sanford C. Bernstein started coverage on Eli Lilly and Company in a research note on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 price objective on the stock. Wells Fargo & Company decreased their target price on Eli Lilly and Company from $1,000.00 to $970.00 and set an “overweight” rating for the company in a research note on Tuesday, January 28th. Finally, Barclays dropped their price target on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a research report on Thursday, October 31st. Five analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $997.50.

Eli Lilly and Company Trading Up 3.4 %

Eli Lilly and Company stock opened at $870.56 on Friday. The company has a market cap of $826.44 billion, a price-to-earnings ratio of 94.11, a P/E/G ratio of 1.72 and a beta of 0.42. The firm has a 50-day moving average of $786.57 and a 200-day moving average of $843.28. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. Eli Lilly and Company has a one year low of $707.02 and a one year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. On average, equities analysts expect that Eli Lilly and Company will post 12.85 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be issued a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.69%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend is Friday, February 14th. Eli Lilly and Company’s payout ratio is presently 56.22%.

Eli Lilly and Company declared that its Board of Directors has approved a share repurchase plan on Monday, December 9th that permits the company to repurchase $15.00 billion in shares. This repurchase authorization permits the company to buy up to 2% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.